These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38727899)

  • 1. Spectrum of NMDA Receptor Variants in Neurodevelopmental Disorders and Epilepsy.
    Gjerulfsen CE; Krey I; Klöckner C; Rubboli G; Lemke JR; Møller RS
    Methods Mol Biol; 2024; 2799():1-11. PubMed ID: 38727899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo GRIN2A variants associated with epilepsy and autism and literature review.
    Mangano GD; Riva A; Fontana A; Salpietro V; Mangano GR; Nobile G; Orsini A; Iacomino M; Battini R; Astrea G; Striano P; Nardello R
    Epilepsy Behav; 2022 Apr; 129():108604. PubMed ID: 35217385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-associated GRIN protein truncating variants trigger NMDA receptor loss-of-function.
    Santos-Gómez A; Miguez-Cabello F; García-Recio A; Locubiche-Serra S; García-Díaz R; Soto-Insuga V; Guerrero-López R; Juliá-Palacios N; Ciruela F; García-Cazorla À; Soto D; Olivella M; Altafaj X
    Hum Mol Genet; 2021 Feb; 29(24):3859-3871. PubMed ID: 33043365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GRIN2A-related disorders: genotype and functional consequence predict phenotype.
    Strehlow V; Heyne HO; Vlaskamp DRM; Marwick KFM; Rudolf G; de Bellescize J; Biskup S; Brilstra EH; Brouwer OF; Callenbach PMC; Hentschel J; Hirsch E; Kind PC; Mignot C; Platzer K; Rump P; Skehel PA; Wyllie DJA; Hardingham GE; van Ravenswaaij-Arts CMA; Lesca G; Lemke JR;
    Brain; 2019 Jan; 142(1):80-92. PubMed ID: 30544257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo GRIN variants in M3 helix associated with neurological disorders control channel gating of NMDA receptor.
    Xu Y; Song R; Perszyk RE; Chen W; Kim S; Park KL; Allen JP; Nocilla KA; Zhang J; XiangWei W; Tankovic A; McDaniels ED; Sheikh R; Mizu RK; Karamchandani MM; Hu C; Kusumoto H; Pecha J; Cappuccio G; Gaitanis J; Sullivan J; Shashi V; Petrovski S; Jauss RT; Lee HK; Bozarth X; Lynch DR; Helbig I; Pierson TM; Boerkoel CF; Myers SJ; Lemke JR; Benke TA; Yuan H; Traynelis SF
    Cell Mol Life Sci; 2024 Mar; 81(1):153. PubMed ID: 38538865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice.
    Amador A; Bostick CD; Olson H; Peters J; Camp CR; Krizay D; Chen W; Han W; Tang W; Kanber A; Kim S; Teoh J; Sah M; Petri S; Paek H; Kim A; Lutz CM; Yang M; Myers SJ; Bhattacharya S; Yuan H; Goldstein DB; Poduri A; Boland MJ; Traynelis SF; Frankel WN
    Brain; 2020 Jul; 143(7):2039-2057. PubMed ID: 32577763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct roles of
    Myers SJ; Yuan H; Kang JQ; Tan FCK; Traynelis SF; Low CM
    F1000Res; 2019; 8():. PubMed ID: 31807283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders.
    Tang W; Liu D; Traynelis SF; Yuan H
    Neuropharmacology; 2020 Oct; 177():108247. PubMed ID: 32712275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human GRIN2B variants in neurodevelopmental disorders.
    Hu C; Chen W; Myers SJ; Yuan H; Traynelis SF
    J Pharmacol Sci; 2016 Oct; 132(2):115-121. PubMed ID: 27818011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradigmatic De Novo
    Santos-Gómez A; Miguez-Cabello F; Juliá-Palacios N; García-Navas D; Soto-Insuga V; García-Peñas JJ; Fuentes P; Ibáñez-Micó S; Cuesta L; Cancho R; Andreo-Lillo P; Gutiérrez-Aguilar G; Alonso-Luengo O; Málaga I; Hedrera-Fernández A; García-Cazorla À; Soto D; Olivella M; Altafaj X
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-Serine Treatment is Associated with Improvements in Behavior, EEG, and Seizure Frequency in Individuals with GRIN-Related Disorders Due to Null Variants.
    Krey I; von Spiczak S; Johannesen KM; Hikel C; Kurlemann G; Muhle H; Beysen D; Dietel T; Møller RS; Lemke JR; Syrbe S
    Neurotherapeutics; 2022 Jan; 19(1):334-341. PubMed ID: 34997442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors.
    Mullier B; Wolff C; Sands ZA; Ghisdal P; Muglia P; Kaminski RM; André VM
    Neuropharmacology; 2017 Sep; 123():322-331. PubMed ID: 28533163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-Associated Variants in GRIN1, GRIN2A and GRIN2B genes: Insights into NMDA Receptor Structure, Function, and Pathophysiology.
    Korinek M; Candelas Serra M; Abdel Rahman F; Dobrovolski M; Kuchtiak V; Abramova V; Fili K; Tomovic E; Hrcka Krausova B; Krusek J; Cerny J; Vyklicky L; Balik A; Smejkalova T
    Physiol Res; 2024 May; 73(Suppl 1):S413-S434. PubMed ID: 38836461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities for Precision Treatment of
    Han W; Yuan H; Allen JP; Kim S; Shaulsky GH; Perszyk RE; Traynelis SF; Myers SJ
    J Pharmacol Exp Ther; 2022 Apr; 381(1):54-66. PubMed ID: 35110392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GRIN1 variants associated with neurodevelopmental disorders reveal channel gating pathomechanisms.
    Ragnarsson L; Zhang Z; Das SS; Tran P; Andersson Å; des Portes V; Desmettre Altuzarra C; Remerand G; Labalme A; Chatron N; Sanlaville D; Lesca G; Anggono V; Vetter I; Keramidas A
    Epilepsia; 2023 Dec; 64(12):3377-3388. PubMed ID: 37734923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-serine treatment in patients with GRIN-related encephalopathy: a phase 2A, non-randomized study.
    Juliá-Palacios N; Olivella M; Sigatullina Bondarenko M; Ibáñez-Micó S; Muñoz-Cabello B; Alonso-Luengo O; Soto-Insuga V; García-Navas D; Cuesta-Herraiz L; Andreo-Lillo P; Aguilera-Albesa S; Hedrera-Fernández A; González Alguacil E; Sánchez-Carpintero R; Martín Del Valle F; Jiménez González E; Cean Cabrera L; Medina-Rivera I; Perez-Ordoñez M; Colomé R; Lopez L; Engracia Cazorla M; Fornaguera M; Ormazabal A; Alonso-Colmenero I; Illescas KS; Balsells-Mejía S; Mari-Vico R; Duffo Viñas M; Cappuccio G; Terrone G; Romano R; Manti F; Mastrangelo M; Alfonsi C; de Siqueira Barros B; Nizon M; Gjerulfsen CE; Muro VL; Karall D; Zeiner F; Masnada S; Peterlongo I; Oyarzábal A; Santos-Gómez A; Altafaj X; García-Cazorla Á
    Brain; 2024 May; 147(5):1653-1666. PubMed ID: 38380699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional assessment of triheteromeric NMDA receptors containing a human variant associated with epilepsy.
    Marwick KFM; Hansen KB; Skehel PA; Hardingham GE; Wyllie DJA
    J Physiol; 2019 Mar; 597(6):1691-1704. PubMed ID: 30604514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes.
    Endele S; Rosenberger G; Geider K; Popp B; Tamer C; Stefanova I; Milh M; Kortüm F; Fritsch A; Pientka FK; Hellenbroich Y; Kalscheuer VM; Kohlhase J; Moog U; Rappold G; Rauch A; Ropers HH; von Spiczak S; Tönnies H; Villeneuve N; Villard L; Zabel B; Zenker M; Laube B; Reis A; Wieczorek D; Van Maldergem L; Kutsche K
    Nat Genet; 2010 Nov; 42(11):1021-6. PubMed ID: 20890276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GRIN2A-related epilepsy and speech disorders: A comprehensive overview with a focus on the role of precision therapeutics.
    Samanta D
    Epilepsy Res; 2023 Jan; 189():107065. PubMed ID: 36516565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel missense mutation in GRIN2A causes a nonepileptic neurodevelopmental disorder.
    Fernández-Marmiesse A; Kusumoto H; Rekarte S; Roca I; Zhang J; Myers SJ; Traynelis SF; Couce ML; Gutierrez-Solana L; Yuan H
    Mov Disord; 2018 Jul; 33(6):992-999. PubMed ID: 29644724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.